Loading clinical trials...
Loading clinical trials...
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Telik
NCT03520647 · Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), and more
NCT05143996 · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
NCT05534620 · Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), and more
NCT02143830 · Fanconi Anemia, Severe Marrow Failure, and more
NCT00923442 · Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome (MDS), and more
Bay Area Cancer Research Group
Concord, California
University of Colorado
Aurora, Colorado
SIU School of Medicine, Simmons Cancer Institute
Springfield, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions